Title: Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin
Authors: de Haan, Willeke ×
de Vries-van der Weij, Jitske
van der Hoorn, José W A
Gautier, Thomas
van der Hoogt, Caroline C
Westerterp, Marit
Romijn, Johannes A
Jukema, J Wouter
Havekes, Louis M
Princen, Hans M G
Rensen, Patrick C N #
Issue Date: May-2008
Publisher: Lippincott Williams & Wilkins
Series Title: Circulation vol:117 issue:19 pages:2515-22
Article number: 10.1161/CIRCULATIONAHA.107.761965
Abstract: Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiovascular death in the recent Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial. Therefore, we evaluated the antiatherogenic potential and adverse effects of torcetrapib in humanized APOE*3-Leiden.CETP (E3L.CETP) mice.
ISSN: 0009-7322
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science